Assembly Biosciences, Inc earnings per share and revenue
On Nov 10, 2025, ASMB reported earnings of -0.72 USD per share (EPS) for Q3 25, beating the estimate of -0.79 USD, resulting in a 8.88% surprise. Revenue reached 10.79 million, compared to an expected 7.61 million, with a 41.80% difference. The market reacted with a +3.31% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analysts forecast an EPS of -0.66 USD, with revenue projected to reach 7.57 million USD, implying an decrease of -8.33% EPS, and decrease of -29.82% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Teva Pharmaceutical Industries Limited - ADR
Report Date
Jan 28, 2026 For Q4 25
Estimate
$0.69
Actual
$0.96
Surprise
+38.55%
Dr. Reddy's Laboratories Limited - ADR
Report Date
Jan 21, 2026 For Q3 26
Estimate
$13.86
Actual
$14.65
Surprise
+5.66%
FAQ
What were Assembly Biosciences, Inc's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Assembly Biosciences, Inc reported EPS of -$0.72, beating estimates by 8.88%, and revenue of $10.79M, 41.8% above expectations.
How did the market react to Assembly Biosciences, Inc's Q3 2025 earnings?
The stock price moved up 3.31%, changed from $32.07 before the earnings release to $33.13 the day after.
When is Assembly Biosciences, Inc expected to report next?
The next earning report is scheduled for Mar 18, 2026.
What are the forecasts for Assembly Biosciences, Inc's next earnings report?
Based on 6
analysts, Assembly Biosciences, Inc is expected to report EPS of -$0.66 and revenue of $7.57M for Q4 2025.